Media headlines about BioMarin Pharmaceutical (NASDAQ:BMRN) have been trending somewhat positive on Wednesday, according to Accern Sentiment. The research group scores the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. BioMarin Pharmaceutical earned a news sentiment score of 0.11 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 46.9387746202118 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news articles that may have effected Accern Sentiment Analysis’s rankings:
- BioMarin Pharma (BMRN) Announces Presentations at ASH (streetinsider.com)
- These 5 companies could disappear in 2018’s wave of M&A (finance.yahoo.com)
- BioMarin Announces Presentations at 59th American Society of Hematology Annual Meeting & Exposition (finance.yahoo.com)
- Here’s Why Sarepta Stock is Up More Than 70% in 6 Months (zacks.com)
- Here's Why Sarepta Stock is Up More Than 70% in 6 Months (finance.yahoo.com)
A number of equities analysts have weighed in on the stock. Deutsche Bank reissued a “buy” rating and issued a $119.00 price objective (up from $118.00) on shares of BioMarin Pharmaceutical in a research report on Wednesday, August 9th. Jefferies Group reissued a “buy” rating and issued a $116.00 price objective on shares of BioMarin Pharmaceutical in a research report on Tuesday, September 26th. J P Morgan Chase & Co set a $131.00 price target on shares of BioMarin Pharmaceutical and gave the stock a “buy” rating in a research report on Monday, November 27th. BidaskClub cut shares of BioMarin Pharmaceutical from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 17th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $113.00 price target on shares of BioMarin Pharmaceutical in a research report on Thursday, September 21st. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and sixteen have assigned a buy rating to the stock. BioMarin Pharmaceutical has an average rating of “Hold” and a consensus price target of $111.59.
Shares of BioMarin Pharmaceutical (BMRN) traded up $0.06 during trading hours on Wednesday, hitting $80.82. 1,188,895 shares of the company’s stock traded hands, compared to its average volume of 1,225,163. BioMarin Pharmaceutical has a 12 month low of $79.50 and a 12 month high of $100.51. The company has a current ratio of 4.91, a quick ratio of 3.81 and a debt-to-equity ratio of 0.41.
BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings results on Thursday, October 26th. The biotechnology company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.06. BioMarin Pharmaceutical had a negative net margin of 12.45% and a negative return on equity of 4.60%. The company had revenue of $334.18 million for the quarter, compared to analyst estimates of $347.38 million. During the same quarter last year, the business earned $0.02 earnings per share. BioMarin Pharmaceutical’s revenue was up 19.4% compared to the same quarter last year. sell-side analysts predict that BioMarin Pharmaceutical will post -0.65 EPS for the current year.
In other BioMarin Pharmaceutical news, EVP George Eric Davis sold 1,200 shares of the firm’s stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $85.64, for a total value of $102,768.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Henry J. Fuchs sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $90.50, for a total transaction of $1,357,500.00. Following the completion of the sale, the insider now owns 141,422 shares in the company, valued at approximately $12,798,691. The disclosure for this sale can be found here. Insiders sold 41,886 shares of company stock worth $3,839,086 in the last 90 days. 1.85% of the stock is owned by company insiders.
COPYRIGHT VIOLATION WARNING: This article was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://ledgergazette.com/2017/12/06/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-biomarin-pharmaceutical-bmrn-stock-price.html.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.